InvestorsHub Logo
Followers 0
Posts 59
Boards Moderated 0
Alias Born 11/07/2017

Re: None

Wednesday, 10/30/2019 1:04:10 AM

Wednesday, October 30, 2019 1:04:10 AM

Post# of 403102
Interesting article....
Gottlieb (ex-fda) said the sector’s low valuations create an opportunity to roll up therapies into a larger company focused on making antibiotics.

“After the Achaogen episode, a lot of valuations have been driven down quite dramatically. I think there’s an opportunity to try to find some existing assets and maybe build a company around those assets,” he said.

That’s what I think I’d be interested in doing,” Gottlieb said. “There are other investors that are interested in this as well. I think the capital is out there to do that.”

While at the FDA, Gottlieb advocated finding new ways to pay for antibiotics, such as a licensing model that would charge hospitals upfront for access to new kinds of anti-infective drugs rather than paying for them on a per unit basis.

https://www.reuters.com/article/us-healthcare-gottlieb-investing-idUSKBN1X82LR
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News